|
|
Equity capital |
Reserves |
Gains/losses recognized |
|
|
| |||||
|
€ million |
General |
Subscribed |
Capital |
Retained |
Actuarial |
Available-for-sale |
Derivative |
Exchange |
Equity attributable to shareholders |
Non-controlling |
Equity |
|
Balance as of January 1, 2010 |
397.2 |
168.0 |
3,813.7 |
4,733.7 |
–228.7 |
18.8 |
47.5 |
509.9 |
9,460.1 |
53.5 |
9,513.6 |
|
Profit after tax |
– |
– |
– |
374.8 |
– |
– |
– |
– |
374.8 |
6.6 |
381.5 |
|
Gains/losses recognized immediately in equity |
– |
– |
– |
– |
–73.3 |
–20.3 |
–87.4 |
1,250.9 |
1,069.9 |
9.6 |
1,079.5 |
|
Comprehensive income |
– |
– |
– |
374.8 |
–73.3 |
–20.3 |
–87.4 |
1,250.9 |
1,444.8 |
16.2 |
1,461.0 |
|
Dividend payments |
– |
– |
– |
–64.6 |
– |
– |
– |
– |
–64.6 |
–6.9 |
–71.6 |
|
Profit transfers to/from E. Merck KG including transfers to reserves |
– |
– |
– |
–109.6 |
– |
– |
– |
– |
–109.6 |
– |
–109.6 |
|
Changes in scope of consolidation/Other |
– |
– |
– |
–2.0 |
– |
– |
– |
– |
–2.0 |
1.1 |
–0.9 |
|
Balance as of June 30, 2010 |
397.2 |
168.0 |
3,813.7 |
4,932.3 |
–302.0 |
–1.5 |
–39.9 |
1,760.8 |
10,728.6 |
63.9 |
10,792.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2011 |
397.2 |
168.0 |
3,813.7 |
5,040.9 |
–370.4 |
–3.1 |
–61.1 |
1,344.6 |
10,329.8 |
42.0 |
10,371.8 |
|
Profit after tax |
– |
– |
– |
255.2 |
– |
– |
– |
– |
255.2 |
5.0 |
260.1 |
|
Gains/losses recognized immediately in equity |
– |
– |
– |
– |
–1.4 |
2.7 |
9.4 |
–35.7 |
–25.0 |
–3.2 |
–28.2 |
|
Comprehensive income |
– |
– |
– |
255.2 |
–1.4 |
2.7 |
9.4 |
–35.7 |
230.1 |
1.8 |
231.9 |
|
Dividend payments |
– |
– |
– |
–80.8 |
– |
– |
– |
– |
–80.8 |
–3.4 |
–84.1 |
|
Profit transfers to/from E. Merck KG including transfers to reserves |
– |
– |
– |
–166.6 |
– |
– |
– |
– |
–166.6 |
– |
–166.6 |
|
Changes in scope of consolidation/Other |
– |
– |
– |
–1.7 |
– |
– |
– |
– |
–1.7 |
1.3 |
–0.4 |
|
Balance as of June 30, 2011 |
397.2 |
168.0 |
3,813.7 |
5,047.0 |
–371.9 |
–0.4 |
–51.7 |
1,308.9 |
10,310.9 |
41.7 |
10,352.6 |